SANOFI CONS HEALTHC IND L Latest Share Price (SANOFICONR)
TODAY IN ONE LINE
SANOFICONR fell 1.6% on light volume, lagging Nifty's -0.3% move, hovering dangerously near its 52-week low.
With a market cap of ₹9,313.58 Cr., it trades at a P/E of 35.01. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SANOFI CONS HEALTHC IND L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 35.7% YoY
- ●High Capital EfficiencyROCE of 2813.8% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 67.2%
- ●Healthy Operating MarginsOPM is structurally strong at 37.0%
- ●Steady Dividend YieldReliable 1.85% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Promoter SellingPromoter holding decreased by 71.27% QoQ
Latest SANOFI CONS HEALTHC IND L News
What changed recently?
Recent events, corporate actions, and announcements.
SANOFI CONS HEALTHC IND L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SANOFI CONS HEALTHC IND L, framed against the sector median so the premium or discount is obvious at a glance.
SANOFI CONS HEALTHC IND L trades at a P/E of 35.01× and P/B of 26.77×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SANOFI CONS HEALTHC IND L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SANOFI CONS HEALTHC IND L — derived from the latest tape, not yesterday's close.
SANOFI CONS HEALTHC IND L last traded at ₹4,023.4 with an intraday range of ₹4,001.1–₹4,113.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹4023.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 4315.70 | +292.30 | +7.26% |
| R3 | 4203.30 | +179.90 | +4.47% |
| R2 | 4158.40 | +135.00 | +3.36% |
| R1 | 4090.90 | +67.50 | +1.68% |
| PIVOT | 4046.00 | 22.60 | 0.56% |
| CURRENT | 4023.40 | — | — |
| S1 | 3978.50 | -44.90 | -1.12% |
| S2 | 3933.60 | -89.80 | -2.23% |
| S3 | 3866.10 | -157.30 | -3.91% |
| S4 | 3753.70 | -269.70 | -6.70% |
SANOFICONR is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹4029–₹4100.1
Trading Below opening range, showing Bearishness
SANOFI CONS HEALTHC IND L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SANOFI CONS HEALTHC IND L — consolidated or standalone — with margins, YoY growth and key ratios inline.
SANOFI CONS HEALTHC IND L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹9,313.58 Cr. and reported EPS of ₹29.87.
SANOFI CONS HEALTHC IND L segment analysis : revenue and profit mix.
Disclosed business segments at SANOFI CONS HEALTHC IND L with their share of revenue and profit, switchable between consolidated and standalone reporting.
SANOFI CONS HEALTHC IND L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SANOFI CONS HEALTHC IND L.
Our AI distills the core fundamental drivers supporting SANOFI CONS HEALTHC IND L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
SANOFI CONS HEALTHC IND L's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 46 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 62% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.93%.
SANOFI CONS HEALTHC IND L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SANOFI CONS HEALTHC IND L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SANOFI CONS HEALTHC IND L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SANOFI CONS HEALTHC IND L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SANOFI CONS HEALTHC IND L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SANOFI CONS HEALTHC IND L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SANOFI CONS HEALTHC IND L stood at 59.9% of traded volume, against a 20-day average of 61.3%.
SANOFI CONS HEALTHC IND L announcements: results, concalls, ratings, M&A.
Filings SANOFI CONS HEALTHC IND L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SANOFI CONS HEALTHC IND L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 86 documents below.
Copy of Newspaper Publication
Sanofi Consumer Healthcare India Limited has informed the Exchange about Copy of Newspaper Publication of Unaudited Financial Result for the quarter…
Press Release
Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated July 28, 2026.
Outcome of Board Meeting
Sanofi Consumer Healthcare India Limited has submitted to the Exchange, the Unaudited Financial Results for the quarter and half year ended Jun 30,…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Sanofi Consumer Healthcare India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Shareholders meeting
Sanofi Consumer Healthcare India Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on Jun 26, 2026.…
Investor decks & rating reports.
SANOFI CONS HEALTHC IND L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SANOFI CONS HEALTHC IND L has declared, sequenced by announce and record date.
SANOFI CONS HEALTHC IND L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
SANOFI CONS HEALTHC IND L insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in SANOFI CONS HEALTHC IND L as reported to SEBI — buying and selling signals from the people who know the business best.
SANOFI CONS HEALTHC IND L insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Opal Bidco SAS | Insider | 11 Jun 2025 | buy | +25.05 L | ₹1,247.82 Cr. | ₹4,982.05 |
About SANOFI CONS HEALTHC IND L: business, sector, key facts.
What SANOFI CONS HEALTHC IND L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SANOFI CONS HEALTHC IND L operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SANOFICONR, BSE: 544250.
SANOFI CONS HEALTHC IND L
Sanofi Consumer Healthcare India Limited is a relatively new player in the Indian fast-moving consumer healthcare (FMCG) market, having been incorporated in 2023. The company focuses on providing over-the-counter (OTC) health solutions, specializing in three key areas: allergy relief, physical wellness, and pain management. Its operations are primarily within India, leveraging a multifaceted distribution network to reach consumers.
The company's product portfolio boasts a collection of established and recognizable brands catering to diverse health needs. These include Allegra for allergy relief, Combiflam for pain relief and fever reduction, Avil, another allergy medication, DePURA for digestive health, Festal for digestive enzyme support, and Novalgin NU, also for pain relief. This breadth of offerings allows them to target a wide range of consumer demographics and health concerns.
Sanofi Consumer Healthcare India's distribution strategy is comprehensive, utilizing a multi-channel approach to reach its target market. This network includes partnerships with distributors and wholesalers, direct sales to government institutions and hospitals, supply to pharmacies and pharmacy chains, and an expanding presence in the e-commerce sector. This diversified approach ensures widespread availability and accessibility of their products across various retail channels.
The company's organizational structure positions it as a subsidiary of Sanofi India Limited, benefiting from the resources and established presence of its parent company. This affiliation provides access to established research and development capabilities, marketing expertise, and a well-recognized brand name, offering a significant advantage in a competitive market. Based in Mumbai, the company leverages its strategic location to effectively manage its operations within India.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week low (reversal watch)Screener
- Reversal Hunter strategy playbookStrategy
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SANOFI CONS HEALTHC IND L (SANOFICONR).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The current share price of SANOFI CONS HEALTHC IND L (SANOFICONR) is ₹4,023.40. Today, the stock has declined by ₹66.20 (1.62%), trading in a range of ₹4,001.10 to ₹4,113.50. The stock opened at ₹4,099.00 with a trading volume of 4,396 shares.
02Is SANOFI CONS HEALTHC IND L stock a good investment for long-term?
SANOFI CONS HEALTHC IND L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹9,313.58 Cr., P/E ratio of 35.01, ROE of 67.16%, and ROCE of 2,813.76%. The dividend yield stands at 1.85%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SANOFI CONS HEALTHC IND L stock?
The 52-week high price of SANOFI CONS HEALTHC IND L (SANOFICONR) is ₹5,357.00, while the 52-week low is ₹3,975.00. Currently trading at ₹4,023.40, the stock is 1.22% above its 52-week low and 24.89% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SANOFI CONS HEALTHC IND L stock at the current price?
Whether to buy SANOFI CONS HEALTHC IND L stock at ₹4,023.40 depends on multiple factors. The stock is currently trading with a P/E ratio of 35.01 and P/B ratio of 26.77. Today's performance shows a loss of 1.62%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SANOFI CONS HEALTHC IND L and when is the next dividend?
SANOFI CONS HEALTHC IND L offers a dividend yield of 1.85%, which means for every ₹100 invested at the current price of ₹4,023.40, you can expect to receive approximately ₹1.85 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SANOFI CONS HEALTHC IND L?
SANOFI CONS HEALTHC IND L's key financial metrics include: P/E Ratio: 35.01, P/B Ratio: 26.77, ROE: 67.16%, ROCE: 2,813.76%, Dividend Yield: 1.85%, EPS: ₹29.87, Book Value: ₹166.73, and Debt-to-Equity: 0. The company's market cap stands at ₹9,313.58 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SANOFI CONS HEALTHC IND L stock performing today in the market?
SANOFI CONS HEALTHC IND L stock opened at ₹4,099.00 and is currently trading at ₹4,023.40, showing a decline of ₹66.20 (1.62%). The intraday high is ₹4,113.50 and low is ₹4,001.10. The trading volume stands at 4,396 shares, indicating moderate market participation today.
08What is the P/E ratio of SANOFI CONS HEALTHC IND L and what does it indicate?
SANOFI CONS HEALTHC IND L has a Price-to-Earnings (P/E) ratio of 35.01, which means investors are willing to pay 35.01 for every ₹1 of earnings. With an EPS of ₹29.87, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SANOFI CONS HEALTHC IND L (SANOFICONR) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.